Scientific Program
Thursday, September 27, 2018
| Hall A | |||
| 14:00-15:30 | Hematology hot news session Chairs: Mohamad Mohty, France; Arnon Nagler, Israel |
||
| 14:00-14:30 | Introduction to IACH Meeting Co-Chairs |
||
| 14:30-14:40 | Ibrutinib plus Venetoclax for the treatment of mantle-cell lymphoma Olivier Hermine, France |
||
| 14:40-14:50 | Ivosidenib in mutant IDH1 relapsed/refractory acute myeloid leukemia Norbert Vey, France |
||
| 14:50-15:00 | Letermovir prophylaxis for CMV in hematopoietic-cell transplantation Bipin Savani, USA |
||
| 15:00-15:10 | Management of hairy cell leukemia – an update Elena Solomou, Greece |
||
| 15:10-15:20 | The RELEVANCE study: Lenalidomide and Rituximab vs Chemotherapy and Rituximab in untreated follicular lymphoma Gandhi Damaj, France |
||
| 15:20-15:30 | Update on therapy of sickle cell disease Selim Corbacioglu, Germany |
||
| 15:30-16:00 | Coffee Break | ||
| 16:00-17:15 | Plenary session 1: New frontiers and novel drugs in hematology: from the bench to the bedside Chairs: Norbert-Claude Gorin, France; Bipin Savani, USA |
||
| 16:00-16:20 | Novel anticoagulation agents Gili Kenet, Israel |
||
| 16:20-16:40 | CAR-T cells in multiple myeloma Hermann Einsele, Germany |
||
| 16:40-17:00 | Advances in CLL therapy Mohamad Kharfan-Dabaja, USA |
||
| 17:00-17:20 | Modulation of the microbiome Philippe Langella, France |
||
| 17:20-17:30 | Discussion | ||
| 17:30-17:45 | Break | ||
| 17:45-19:00 | Opening session: Keynote opening lectures and awards Chairs: Mohamad Mohty, France; Arnon Nagler, Israel |
||
| 17:45-18:00 | Award presentation (H.J. Khoury Excellence in Research Award) | ||
| 18:00-18:30 | Multiple myeloma – past, present and future Jean-Luc Harousseau, France |
||
| 18:30-19:00 | Advances in the treatment of acute lymphoblastic leukemia Hagop Kantarjian, USA |
||
| 19:00 | Welcome Reception | ||
Friday, September 28, 2018
| Hall A | Hall B |
||
| 09:00-10:30 | Session F1A: Multiple myeloma Chairs: Meral Baksaç, Turkey; Mohamad Mohty, France |
09:00-10:30 | Session F1B: Allogeneic stem cell transplant indications Chairs: Ibrahim Yakoub-Agha, France; Marcos de Lima, USA |
| 09:00-09:20 | Debate: Chemo-free stem cell mobilization in myeloma Con: Rafael Duarte, Spain |
09:00-09:20 | Acute lymphoblastic leukemia Sebastian Giebel, Poland |
| 09:20-09:40 | Pro: Christian Chabannon, France | 09:20-09:40 | Acute myeloid leukemia Arnon Nagler, Israel |
| 09:40-10:00 | The patient perspective – examples from multiple myeloma Karthik Ramasamy, UK |
09:40-10:00 | Myelodysplastic syndromes Ibrahim Yakoub-Agha, France |
| 10:00-10:20 | Monoclonal antibodies in myeloma Mohamad Mohty, France |
10:00-10:20 | Myeloproliferative neoplasms Marcos de Lima, USA |
| 10:20-10:30 | Discussion | 10:20-10:30 | Discussion |
| 10:30-11:00 | Coffee Break, Poster Viewing and Visit Exhibition | ||
| 11:00-12:30 | Session F2A: Acute myeloid leukemia (AML) Chairs: Jose Eduardo Guimaraes, Portugal; Bob Löwenberg, Netherlands |
11:00-12:30 | Session F2B: Cellular and immune therapy in hematologic malignancies Chairs: Christian Chabannon, France; Jürgen Kuball, Netherlands |
| 11:00-11:20 | Role of MRD in AML Maria Gilleece, UK |
11:00-11:20 | The case for gamma-delta T cells Jürgen Kuball, Netherlands |
| 11:20-11:40 | Management of elderly AML Farhad Ravandi, USA |
11:20-11:40 | Calcineurin and mTOR inhibitor-free GvHD prophylaxis: Samer Al-Homsi, USA |
| 11:40-12:00 | How to improve on “3+7”? Bob Löwenberg, Netherlands |
11:40-12:00 | Intersection between immunology and metabolic complications after HCT Brian Engelhardt, USA |
| 12:00-12:20 | Supportive care in AML Bipin Savani, USA |
12:00-12:20 | What role could allotransplantation have in CAR-T cell therapy? Stephan Mielke, Sweden |
| 12:20-12:30 | Discussion | 12:20-12:30 | Discussion |
| 12:30-12:45 | Lunch Box Pick-up | ||
| 12:45-13:45 | Industry Symposium Hall A |
||
| 13:45-14:00 | Short Break | ||
| 14:oo-15:30 | Session F3A: Non-Hodgkin lymphoma Chairs: Christian Gisselbrecht, France; Mohamad Kharfan-Dabaja, USA |
14:00-15:30 | Session F3B: Allogeneic stem cell transplant complications Chairs: Multu Arat, Turkey; Enric Carreras, Spain |
| 14:00-14:20 | Advances in lymphoma biology Fabrice Jardin, France |
14:00-14:20 | Management of endothelium-related complications Enric Carreras, Spain |
| 14:20-14:40 | Therapy of high grade lymphoma Christian Gisselbrecht, France |
14:20-14:40 | Management of viral infections Per Ljungman, Sweden |
| 14:40-15:00 | Therapy of HTLV-related lymphoma Ali Bazarbachi, Lebanon |
14:40-15:00 | Management of acute GVHD Florent Malard, France |
| 15:00-15:20 | Advances in Waldenström Macroglobulinemia: Irene Ghobrial, USA |
15:00-15:20 | Prevention and management of long term complications Grzegorz Basak, Poland |
| 15:20-15:30 | Discussion | 15:20-15:30 | Discussion |
| 15:30-16:00 | Coffee Break, Poster Viewing and Visit Exhibition | ||
| 16:00-17:30 | Session F4A: Acute lymphoblastic leukemia (ALL) Chairs: Sebastian Giebel, Poland; Elias Jabbour, USA |
16:00-17:30 | Session F4B: Advances in allogeneic stem cell transplantation Chairs: Didier Blaise, France; Steven Pavletic, USA |
| 16:00-16:20 | Risk stratification and MRD in ALL: Christopher Hourigan, USA |
16:00-16:20 | Choice of donors for haplo-identical transplantation Yu Wang, China |
| 16:20-16:40 | Novel antibodies in relapsed/refractory ALL Eolia Brissot, France |
16:20-16:40 | Results of haplo transplants in acute leukemia Didier Blaise, France |
| 16:40-17:00 | Intensive therapy for ALL Dieter Hoelzer, Germany |
16:40-17:00 | Results of cord blood transplants in children Annalisa Ruggeri, France/Italy |
| 17:00-17:20 | Management of elderly ALL Elias Jabbour, USA |
17:00-17:20 | Novel therapies for chronic GVHD Steven Pavletic, USA |
| 17:20-17:30 | Discussion | 17:20-17:30 | Discussion |
| 17:30-18:30 | Session F5A: Towards personalized and precision medicine Chairs: Annalisa Ruggeri, Italy; Takanori Teshima, Japan |
17:30-18:30 | Session F5B: Case report forum Chairs: Manuel Abecasis, Portugal; Mohamad Mohty, France |
| 17:30-17:50 | Treatment of non-transplant eligible myeloma Thierry Facon, France |
17:30-17:50 | How to write a good paper? Junia Melo, Australia |
| 17:50-18:10 | Pharmacogenomics in stem cell transplantation Shahrukh Hashmi, USA |
17:50-18:00 | Case No. 1 Zina Peric, Croatia |
| 18:10-18:30 | Check-point inhibitors, immune-related adverse events, and GVHD Takanori Teshima, Japan |
18:00-18:10 | Case No. 2 Jean El-Cheikh, Lebanon |
| 18:10-18:20 | Case N0. 3 Rémy Duléry, France |
||
| 18:20-18:30 | Discussion | ||
| 18:30-19:00 | Dinner Buffet | ||
| 19:00-20:00 | Industry Symposium Hall A |
||
| 20:00 | Dessert and Coffee | ||
Saturday, September 29, 2018
| Hall A | Hall B |
||
| 08:30-10:00 | Session S1A: Chronic myeloid leukemia (CML) and polycythemia vera Chairs: Francois Guilhot, France; Giuseppe Saglio, Italy |
08:30-10:00 | Session S1B: Red blood cell disorders Chairs: Borje Andersson, USA; Ali Taher, Lebanon |
| 08:30-08:50 | Update on polycythemia vera therapy Nicole Casadevall, France |
08:30-08:50 | Advances in thalassemia Ali Taher, Lebanon |
| 08:50-09:10 | Long term results of 1st generation TKI Francois Guilhot, France |
08:50-09:10 | Advances in sickle cell disease Miguel Abboud, Lebanon |
| 09:10-09:30 | Role of second generation TKI Giuseppe Saglio, Italy |
09:10-09:30 | Transfusions in red blood cell disorders France Pirenne, France |
| 09:30-09:50 | Stopping TKIs: for whom, when and how? Francois-Xavier Mahon, France |
09:30-09:50 | Allogeneic stem cell transplantation for thalassemia and SCD Borje Andersson, USA |
| 09:50-10:00 | Discussion | 09:50-10:00 | Discussion |
| 10:00-11:00 | Special Session: CAR-T cells – a real-life perspective Chairs: Mohamad Mohty, France; Arnon Nagler, Israel Hall A |
||
| 10:00-10:20 | Cell procurement for CAR-T cells manufacturing: Christian Chabannon, France |
||
| 10:20-10:40 | CAR-T Cells: indications and focus on multiple myeloma: Ali Bazarbachi, Lebanon |
||
| 10:40-11:00 | Management of CAR-T cell toxicities: a real-life example: Mohamad Mohty, France |
||
| 11:00-11:30 | Coffee Break, Poster Viewing and Visit Exhibition | ||
| 11:30-13:00 | Session S2A: Myelodysplastic syndromes, aplastic anemia and other related disorders Chairs: Urpu Salmenniemi, Finland; Carlos Vallejo, Spain |
11:30-13:00 | Session S2B: Rare diseases and orphan conditions Chairs: Miguel Abboud, Lebanon; Olivier Hermine, France |
| 11:30-11:50 | Genetic predisposition in bone marrow failure and MDS Jean Soulier, France |
11:30-11:50 | Systemic mastocytosis Olivier Hermine, France |
| 11:50-12:10 | Management of low risk MDS Pierre Fenaux, France |
11:50-12:10 | Replacement therapy in hemophilia – From proteins to genes Alok Srivastava, India |
| 12:10-12:30 | 2nd line ITP treatment James Bussel, USA |
12:10-12:30 | Gaucher disease Ari Zimran, Israel |
| 12:30-12:50 | Management of aplastic anemia outside transplant Carlos Vallejo, Spain |
12:30-12:50 | Thrombotic thrombocytopenic purpura Paul Coppo, France |
| 12:50-13:00 | Discussion | 12:50-13:00 | Discussion |
| 13:00-13:15 | Lunch Box Pick-up | ||
| 13:15-14:15 | Industry symposium | 13:15-14:15 | Session S3B: IACH lunch debate Chairs: Michel Delforge, Belgium; Graham Jackson, UK |
| Autologous stem cell transplant for systemic amyloidosis | |||
| 13:15-13:35 | Pro: Giovanni Palladini, Italy | ||
| 13:35-13:55 | Con: Arnaud Jaccard, France | ||
| 13:55-14:15 | Discussion | ||
| 14:15-14:25 | Short Break | ||
| 14:25-14:55 | Session S4A: Clinical experiences from around the world Chairs: Norbert-Claude Gorin, France; Shinichiro Okamoto, Japan |
14:25-14:55 | Session S4B: Making the right diagnosis and therapy Chairs: Miguel-Angel Perales, USA; Anna Sureda, Spain |
| 14:25-14:40 | China He Huang, China |
14:25-14:45 | Transplant indications in Hodgkin lymphoma Anna Sureda, Spain |
| 14:40-14:55 | Argentina Gregorio Jaimovich, Argentina |
14:45-15:05 | Monoclonal component Graham Jackson, UK |
| 14:55-15:10 | Turkey Meral Beksac, Turkey |
15:05-15:25 | Hyperferritinemia Pierre Brissot, France |
| 15:10-15:25 | Japan Shinichiro Okamoto, Japan |
15:25-15:45 | MRD-driven therapy in myeloma Michel Delforge, Belgium |
| 15:25-15:40 | India Lalit Kumar, India |
15:45-15:55 | Discussion |
| 15:40-15:55 | Hong Kong James Chim, Hong Kong |
||
| 15:55-16:10 | Presentation of the IACH ICA Award Hall A |
||
| 16:10-16:30 | Coffee Break, Poster Viewing and Visit Exhibition | ||
| 16:30-18:00 | Plenary session 2: CAR-T cells in hematology Hall A Chairs: Mohamad Mohty, France; Arnon Nagler, Israel |
||
| 16:30-16:50 | CAR-T cells explained to clinicians Elad Jacoby, Israel |
||
| 16:50-17:10 | Results of CAR-T cells in acute lymphoblastic leukemia Jordan Gauthier, USA |
||
| 17:10-17:30 | Results in non-Hodgkin lymphoma and CLL Miguel-Angel Perales, USA |
||
| 17:30-17:50 | NK CAR cells: current status and perspectives Katy Rezvani, USA |
||
| 17:50-18:00 | Discussion | ||
| 18:00 | Meeting conclusions and closure | ||